About CV6 Therapeutics
CV6 Therapeutics is a clinical-stage biotechnology company based in Northern Ireland focused on developing investigational combination therapies in oncology and inflammatory disease.
Through investigational medicines designed to work in combination with existing treatments, CV6 is developing therapies intended to enhance existing standards of care. Its lead program, CV6-168, is in Phase 1a trials, with additional programs advancing toward clinical development in autoimmune conditions.
What is CV6?
CV6 Therapeutics is developing a new class of therapies designed to modulate the therapeutic activity of widely used treatments and address mechanisms associated with treatment resistance.
Its lead program, CV6-168, targets a fundamental biological mechanism linked to 5-FU activity and resistance. CV6 is developing therapies designed to enhance the activity of established treatments across multiple major cancers.
Programs
View all
Oncology
CV6 is advancing investigational therapies for cancers where standard treatments remain essential but resistance remains a major clinical challenge.
Inflammatory Diseases
CV6 is applying the same scientific approach to inflammatory diseases, including rheumatoid arthritis, where significant unmet medical needs remain.